221 related articles for article (PubMed ID: 26680066)
1. Autologous Stem Cell Transplantation in Patients With Primary Systemic Amyloidosis: Experience of a Tertiary Hospital.
Domínguez-Muñoz MA; Calderón-Cabrera C; Martino-Galiana ML; Martín-Sánchez J
Transplant Proc; 2015 Nov; 47(9):2661-4. PubMed ID: 26680066
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
3. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
4. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
[TBL] [Abstract][Full Text] [Related]
6. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
8. [Autologous peripheral blood hematopoietic stem cell transplantation for patients with primary light chain amyloidosis: experience of 31 cases in a single center].
Li J; Feng J; Cao XX; Zhang CL; Shen KN; Huang XF; Zhang CL; Duan MH; Zhang W; Zhu TN; Cai HC; Zhang L; Cai H; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):201-4. PubMed ID: 27033756
[TBL] [Abstract][Full Text] [Related]
9. Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.
Kim HR; Yoon SE; Kim D; Choi JO; Min JH; Kim BJ; Kim JS; Lee JE; Choi JY; Jeon ES; Kim SJ; Kim K
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):97-103. PubMed ID: 36464620
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Fuchida SI; Kawamura K; Sunami K; Tsukada N; Fujii S; Ohkawara H; Usuki K; Wake A; Endo S; Ishiyama K; Ueda Y; Nakamura Y; Miyamoto T; Fukuda T; Ichinohe T; Atsuta Y; Takamatsu H
Transplant Cell Ther; 2022 Feb; 28(2):76-82. PubMed ID: 34774818
[TBL] [Abstract][Full Text] [Related]
11. A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.
Sharpley FA; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Whelan CJ; Fontana M; Martinez-Naharro A; Quarta C; Hawkins PN; Wechalekar AD
Br J Haematol; 2019 Dec; 187(5):642-652. PubMed ID: 31410841
[TBL] [Abstract][Full Text] [Related]
12. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
14. Cardiac and autologous stem cell transplantation hematopoietic in patients with AL amyloidosis.
Carretero M; Villanueva E; Brulc EB; Faelo FM; Aguirre MA; Pérez-de-Arenaza D; Belziti CA; Arbelbide JA; Nucifora EM; Posadas-Martinez ML
Arch Cardiol Mex; 2023; 93(4):435-441. PubMed ID: 37972368
[TBL] [Abstract][Full Text] [Related]
15. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.
Xie W; Wang Q; Zhou F; Wang S; Sun Y; Cen X; Ren H; Qiu Z; Dong Y
Int J Hematol; 2023 Aug; 118(2):231-241. PubMed ID: 37247070
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
